Parkinson's Disease: Molecular mechanism, Biomarkers, and advances in therapeutic Development
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and a rising global health challenge, owing to population aging and increasing disease prevalence. Existing therapeutic strategies provide mainly symptomatic relief, but significant progress has been made in understanding the molecular and cellular mechanisms underlying PD that has accelerated the development of disease-modifying interventions. This review summarizes the recent progress in PD research, including advances in disease pathogenesis, biomarker discovery, therapeutic development, and precision medicine. We discuss the complex interplay between α-synuclein aggregation, mitochondrial dysfunction, oxidative stress, neuroinflammation, impaired autophagy-lysosomal and ubiquitin-proteasome systems, dysregulation of the gut-brain axis, and genetic susceptibility as the basis of disease progression. Recent advances in genetic profiling and multi-omics technologies have greatly improved our understanding of disease heterogeneity and identified novel therapeutic targets. The review also provides an overview of established and emerging biomarkers including cerebrospinal fluid α-synuclein seed amplification assays, neurofilament light chain, neuroimaging modalities, digital biomarkers, wearable technologies and artificial intelligenceassisted diagnostic approaches for facilitating early diagnosis and disease monitoring.
Authors
- Neerja Kumari
- Ankita Tripathi
- Mukul Tambe
- Anmol Singh
- Pankaj Singh
- Jyoti Singh
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24338876
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00